BN ImmunoTherapeutics
BN ImmunoTherapeutics was acquired by Bavarian Nordic in 2009; the integrated company is a global vaccine developer and manufacturer based in Denmark, using its proprietary MVA-BN viral vector platform to supply smallpox/mpox vaccines to governments and travel vaccines (rabies, chikungunya, cholera, typhoid, tick-borne encephalitis) to travelers across 70+ countries.
- Company typePublic
- Founded1994
- HeadquartersHellerup, Denmark
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What BN ImmunoTherapeutics does
BN ImmunoTherapeutics was a cancer immunotherapy company that was acquired by Bavarian Nordic in 2009 and has since been integrated into Bavarian Nordic's operations; standalone data for BN ImmunoTherapeutics is no longer available. The integrated entity, Bavarian Nordic, is a global vaccine company headquartered in Hellerup, Denmark, founded in 1994 and listed on Nasdaq Copenhagen since 1998. It specializes in the research, development, and manufacturing of vaccines built on viral vector technology, centered on its proprietary Modified Vaccinia Ankara (MVA-BN) platform, with 30+ years of vaccine development expertise. Its core products include JYNNEOS/IMVAMUNE/IMVANEX (smallpox/mpox, approved in 70+ countries), Rabipur/RabAvert (rabies), Encepur (tick-borne encephalitis), Vaxchora (cholera), VIMKUNYA (chikungunya, with recent approvals across FDA, EC, MHRA, Swissmedic, and Health Canada), and Vivotif (typhoid).
The company operates a two-segment business model. In the public preparedness segment, it supplies governments and supranational organizations with smallpox/mpox vaccines under multi-year procurement contracts, notably including a large US BARDA contract for JYNNEOS. In the commercial travel vaccines segment, it markets Rabipur/RabAvert, Encepur, Vaxchora, VIMKUNYA, and Vivotif to travelers through pharmacies, travel clinics, and HCP portals (BN Assist in the US, BN Online in Canada and Europe). It employs more than 1,600 people across R&D, live-virus manufacturing in Denmark and Switzerland (Kvistgaard and Bern), and global commercialization.
Revenue mechanics blend long-dated government preparedness contracts, which provide predictable volume with lumpier order timing, with shorter-cycle commercial travel vaccine sales that depend on travel patterns and outbreak-driven demand. Recent strategic emphasis is on expanding the commercial vaccine footprint globally (notably through VIMKUNYA approvals and the Serum Institute of India partnership), extending JYNNEOS into pediatric populations via EMA, and scaling manufacturing capacity to support both public preparedness and commercial growth.
BN ImmunoTherapeutics firmographics
Firmographics- Name
- BN ImmunoTherapeutics
- Legal name
- Bavarian Nordic A/S
- Website
- https://bavarian-nordic.com
- Company type
- Public
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- BN ImmunoTherapeutics was acquired by Bavarian Nordic in 2009; the integrated company is a global vaccine developer and manufacturer based in Denmark, using its proprietary MVA-BN viral vector platform to supply smallpox/mpox vaccines to governments and travel vaccines (rabies, chikungunya, cholera, typhoid, tick-borne encephalitis) to travelers across 70+ countries.
- Ownership category
- akta.pro rank
BN ImmunoTherapeutics industry classification
Industry- Product category
- Immuno-therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
- akta.pro secondary industries
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)
Keywords
Where BN ImmunoTherapeutics is headquartered
LocationHeadquarters
- HQ city
- Hellerup
- HQ country
- Denmark
- HQ region
- Europe
Offices13 records
Markets served
BN ImmunoTherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel
Revenue model
- Vaccine Product Sales: Revenue generated from sale of commercial vaccines including travel vaccines (Rabipur/RabAvert, Encepur, Vivotif, Vaxchora, Vimkunya) and government preparedness vaccines (JYNNEOS/IMVAMUNE/IMVANEX for smallpox/mpox)
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
BN ImmunoTherapeutics product offering
Product offeringCore offering
BN ImmunoTherapeutics was a biotechnology company focused on immuno-therapeutics, as suggested by its name. The company was acquired by Bavarian Nordic in 2009 and no longer operates as a standalone entity; the input does not specify the particular therapeutic candidates, modalities, or indications the company pursued.
Product overview
Bavarian Nordic is a global vaccine company with a focused portfolio of travel vaccines and public health preparedness vaccines. The company offers a portfolio of commercial vaccines including JYNNEOS®/IMVAMUNE®/IMVANEX® (smallpox/mpox vaccine), Rabipur®/RabAvert® (rabies vaccine), Encepur® (tick-borne encephalitis), Vaxchora® (cholera), VIMKUNYA™ (chikungunya), and Vivotif® (typhoid). The company also has a pipeline product (MVA-BN WEV) in Phase 2 for equine encephalitis. The company operates its own commercial-scale manufacturing facilities in Denmark and Switzerland.
Differentiator
Problem solved
Functional benefit
Brands
- JYNNEOS® / IMVAMUNE® / IMVANEX®: Smallpox +/- Monkeypox (Mpox) Vaccine, Live, Non-replicating. Marketed under different names in different regions.
- Rabipur® / RabAvert®
- Encepur®
- Vaxchora®
- VIMKUNYA™
- Vivotif®
Products and services
- Immuno-therapeutic assets (pre-acquisition pipeline) Pre-acquisition immuno-therapeutic assets of BN ImmunoTherapeutics; specific candidates, indications, modalities, or commercial products are not documented in the input data.
Quantifiable outcome
- Chikungunya vaccine VIMKUNYA approved by Health Canada (June 2026) - fifth global regulatory approval
- +2 more outcomes
Companies that use BN ImmunoTherapeutics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
BN ImmunoTherapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BN ImmunoTherapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Serum Institute of IndiacoreBavarian Nordic and Serum Institute of India expanded their strategic partnership with a Chikungunya vaccine manufacturing agreement. This partnership expands global access to the chikungunya vaccine VIMKUNYA through Serum Institute's manufacturing capabilities.
- U.S. GovernmentcoreDevelopment contracts with the US government for MVA-BN WEV vaccine candidate addressing western, eastern and Venezuelan equine encephalitis viruses. Bavarian Nordic is also a preferred supplier of smallpox/mpox vaccines to the US government.
- Network of Partners WorldwideminorA network of partners worldwide to expand capacity and supply as needed for vaccine manufacturing and distribution.
Scale indicators7 records
Recent moves8 records
Expansion highlights4 records
BN ImmunoTherapeutics competitors and assessment
Company assessmentBroad incumbents
- Moderna: Moderna is a broader incumbent in the vaccine space with an mRNA platform and a growing infectious disease vaccine portfolio, including mpox vaccine candidates that compete with Bavarian Nordic's JYNNEOS franchise. As a much larger company with multiple approved products globally, Moderna competes across several of Bavarian Nordic's preparedness and travel vaccine markets.
- Sanofi Pasteur: Sanofi Pasteur operates one of the world's largest vaccine franchises spanning pediatric, travel, and endemic disease segments. It competes with Bavarian Nordic's travel vaccines (especially rabies and TBE where it sells VERORAB and other established products) and is a broad incumbent in the same industry space.
- GSK: GSK is a broad incumbent in vaccines, with a global portfolio that historically included the Rabipur/RabAvert and Encepur products Bavarian Nordic acquired in 2019. Although those specific brands moved to Bavarian Nordic, GSK remains a peer in travel health and broader vaccine markets and previously employed several of Bavarian Nordic's current commercial leaders.
- Merck & Co. Merck operates a global vaccine franchise (Gardasil, ProQuad, Vaxneuvance) and competes broadly in the infectious disease vaccine category. While Merck's portfolio skews pediatric and oncology-adjacent, it is a relevant broad incumbent peer for benchmarking vaccine commercialization capabilities and government contracting scale.
- Pfizer: Pfizer is a broad incumbent in vaccines (Prevnar franchise, COVID-19 partnership, mRNA pipeline including mpox candidates) and competes with Bavarian Nordic in U.S. preparedness procurement and in travel vaccines for endemic infectious diseases.
- Takeda Pharmaceutical (Vaccines): Takeda operates a global vaccine franchise acquired from Baxter (including travel vaccines such as Japanese encephalitis) and holds pandemic preparedness contracts with multiple governments. As a Japanese broad incumbent with vaccine manufacturing, Takeda is comparable to Bavarian Nordic's global preparedness positioning.
- Seqirus (CSL): Seqirus, the vaccines arm of CSL Limited, is a broad incumbent in specialty vaccines, particularly influenza but also travel and endemic disease vaccines. Its scale, biosecurity-grade manufacturing footprint, and pandemic preparedness positioning parallel aspects of Bavarian Nordic's business model.
Direct peers
- Emergent BioSolutions: Emergent BioSolutions is a direct peer in the biodefense and public preparedness vaccine space, historically focused on anthrax and smallpox countermeasures sold to U.S. government agencies. Like Bavarian Nordic, Emergent depends heavily on BARDA and similar federal preparedness contracts, and the two companies directly compete for smallpox/mpox preparedness procurement.
- Valneva: Valneva is a direct competitor in travel and endemic infectious disease vaccines, particularly with IXCHIQ (live-attenuated chikungunya vaccine) competing directly against Bavarian Nordic's VIMKUNYA. Both companies are specialty vaccine players focused on travel health markets and have similar commercial infrastructure in Europe and North America.
Emerging players
- Novavax: Novavax is an emerging vaccine specialist focused on recombinant protein nanoparticle platforms, with COVID-19 and broader infectious disease pipeline ambitions. While its portfolio overlaps with Bavarian Nordic only loosely today, it is a comparable emerging vaccine player navigating scale-up, commercialization, and government contracting challenges.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
BN ImmunoTherapeutics social profiles
Digital presenceBN ImmunoTherapeutics compliance and trust
Trust signalCompliance6 records
BN ImmunoTherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BN ImmunoTherapeutics leadership team
Management profileNumber of profiles
BN ImmunoTherapeutics subsidiaries and ownership
Company hierarchySubsidiaries12 records
BN ImmunoTherapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BN ImmunoTherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BN ImmunoTherapeutics
What does BN ImmunoTherapeutics do?
BN ImmunoTherapeutics was a biotechnology company focused on immuno-therapeutics, as suggested by its name. The company was acquired by Bavarian Nordic in 2009 and no longer operates as a standalone entity; the input does not specify the particular therapeutic candidates, modalities, or indications the company pursued.
Is BN ImmunoTherapeutics a public or private company?
BN ImmunoTherapeutics is a public company. It is classified as corporate owned and is currently operating.
When was BN ImmunoTherapeutics founded?
BN ImmunoTherapeutics was founded in 1994. It employs 1,001 to 5,000 people.
Where is BN ImmunoTherapeutics based?
BN ImmunoTherapeutics is headquartered in Hellerup, Denmark, in the Europe region.
How does BN ImmunoTherapeutics make money?
One revenue line is on record: vaccine Product Sales.
Who are BN ImmunoTherapeutics's main competitors?
Broad incumbents on record are Moderna, Sanofi Pasteur, GSK, Merck & Co., Pfizer, Takeda Pharmaceutical (Vaccines) and Seqirus (CSL). Direct peers are Emergent BioSolutions and Valneva. Novavax is listed as an emerging player.
Does BN ImmunoTherapeutics have an API?
No public API is recorded for BN ImmunoTherapeutics.
What industry is BN ImmunoTherapeutics in?
BN ImmunoTherapeutics's product category is Immuno-therapeutics. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325412 and its SIC code is 2834.